CY2608B2 - Φαρμακευτικη συνθεση περιλαμβανουσα πιογλιταζονη και γλιμεπιριδη για χρηση στην θεραπεια του διαβητη - Google Patents

Φαρμακευτικη συνθεση περιλαμβανουσα πιογλιταζονη και γλιμεπιριδη για χρηση στην θεραπεια του διαβητη

Info

Publication number
CY2608B2
CY2608B2 CY0900011A CY0900011A CY2608B2 CY 2608 B2 CY2608 B2 CY 2608B2 CY 0900011 A CY0900011 A CY 0900011A CY 0900011 A CY0900011 A CY 0900011A CY 2608 B2 CY2608 B2 CY 2608B2
Authority
CY
Cyprus
Prior art keywords
treatment
ofdiabetes
pharmaceutical composition
enhancer
diabetes
Prior art date
Application number
CY0900011A
Other languages
English (en)
Inventor
Hitoshi Ikeda
Takashi Sohda
Hiroyuki Odaka
Original Assignee
Takeda Pharmaceutical
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=15563926&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CY2608(B2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Takeda Pharmaceutical filed Critical Takeda Pharmaceutical
Publication of CY2608B2 publication Critical patent/CY2608B2/el

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4245—Oxadiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/64—Sulfonylureas, e.g. glibenclamide, tolbutamide, chlorpropamide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Endocrinology (AREA)
  • Molecular Biology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Biophysics (AREA)
  • Emergency Medicine (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Φαρμακευτικό σκεύασμα το οποίο περιλαμβάνει έναν ενισχυτή της ευαισθησίας της ινσουλίνης σε συνδυασμό με άλλα αντιδιαβητικά που διαφέρουν από τον ενισχυτή στον μηχανισμό δράσης, το οποίο σκεύασμα εμφανίζει μία ισχυρή κατασταλτική επίδραση στην διαβητική υπεργλυκαιμία και είναι χρήσιμο για την προφύλαξη και τη θεραπεία του διαβήτη.
CY0900011A 1995-06-20 2009-10-20 Φαρμακευτικη συνθεση περιλαμβανουσα πιογλιταζονη και γλιμεπιριδη για χρηση στην θεραπεια του διαβητη CY2608B2 (el)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP15350095 1995-06-20

Publications (1)

Publication Number Publication Date
CY2608B2 true CY2608B2 (el) 2010-04-28

Family

ID=15563926

Family Applications (4)

Application Number Title Priority Date Filing Date
CY0400010A CY2424B1 (en) 1995-06-20 2004-02-19 Pharmaceutical composition for use in treatment ofdiabetes.
CY200700001C CY2007001I1 (el) 1995-06-20 2007-01-08 Φαρμακευτικο σκευασμα για χρηση στη θεραπεια του διαβητη
CY0900011A CY2608B2 (el) 1995-06-20 2009-10-20 Φαρμακευτικη συνθεση περιλαμβανουσα πιογλιταζονη και γλιμεπιριδη για χρηση στην θεραπεια του διαβητη
CY2009018C CY2009018I2 (el) 1995-06-20 2009-12-01 Φαρμακευτικη συνθεση περιλαμβανουσα πιογλιταζονη και γλιμεπιριδη για χρηση στην θεραπεια του διαβητη

Family Applications Before (2)

Application Number Title Priority Date Filing Date
CY0400010A CY2424B1 (en) 1995-06-20 2004-02-19 Pharmaceutical composition for use in treatment ofdiabetes.
CY200700001C CY2007001I1 (el) 1995-06-20 2007-01-08 Φαρμακευτικο σκευασμα για χρηση στη θεραπεια του διαβητη

Family Applications After (1)

Application Number Title Priority Date Filing Date
CY2009018C CY2009018I2 (el) 1995-06-20 2009-12-01 Φαρμακευτικη συνθεση περιλαμβανουσα πιογλιταζονη και γλιμεπιριδη για χρηση στην θεραπεια του διαβητη

Country Status (26)

Country Link
US (44) US5952356A (el)
EP (6) EP2289556A3 (el)
JP (3) JP3148973B2 (el)
KR (3) KR970000233A (el)
CN (3) CN1212117C (el)
AR (4) AR005641A1 (el)
AT (2) ATE256463T1 (el)
CA (3) CA2179584C (el)
CY (4) CY2424B1 (el)
CZ (2) CZ291624B6 (el)
DE (4) DE69631157T2 (el)
DK (2) DK0861666T3 (el)
ES (2) ES2327383T5 (el)
FR (1) FR09C0055I2 (el)
HK (2) HK1010484A1 (el)
HU (1) HUP9601698A3 (el)
LU (2) LU91298I2 (el)
MX (1) MX9602399A (el)
MY (1) MY127530A (el)
NL (2) NL300258I2 (el)
NO (5) NO313226B1 (el)
PT (2) PT1174135E (el)
RU (5) RU2198682C2 (el)
SK (2) SK287351B6 (el)
TW (2) TW438587B (el)
ZA (1) ZA965190B (el)

Families Citing this family (254)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW438587B (en) 1995-06-20 2001-06-07 Takeda Chemical Industries Ltd A pharmaceutical composition for prophylaxis and treatment of diabetes
NO318765B1 (no) * 1995-07-03 2005-05-02 Sankyo Co Anvendelse av en HMG-CoA reduktaseinhibitor og en insulinsensibilisator til fremstilling av et medikament for forebyggelse eller behandling av arteriosklerose eller xantom, samt pakket farmasoytisk preparat som omfatter de to midlene i separate porsjoner.
HUP9802543A2 (hu) 1995-08-10 1999-07-28 Warner-Lambert Company Eljárás nem inzulinfüggő diabetes mellitusban szenvedő betegek esetében az adagolt exogén inzulin mennyiségének csökkentésére alkalmas tiazolindion-származékokat tartalmazó gyógyszerkészítmények előállítására
AU713277B2 (en) * 1996-04-05 1999-11-25 Takeda Pharmaceutical Company Limited Pharmaceutical combination containing a compound having angiotensin II and antagonistic activity
WO1998002183A1 (en) 1996-07-15 1998-01-22 Sankyo Company, Limited Medicinal compositions
FR2758459B1 (fr) * 1997-01-17 1999-05-07 Pharma Pass Composition pharmaceutique de fenofibrate presentant une biodisponibilite elevee et son procede de preparation
US5859037A (en) * 1997-02-19 1999-01-12 Warner-Lambert Company Sulfonylurea-glitazone combinations for diabetes
US6011049A (en) * 1997-02-19 2000-01-04 Warner-Lambert Company Combinations for diabetes
US6291495B1 (en) * 1997-02-24 2001-09-18 Robert B. Rieveley Method and composition for the treatment of diabetes
US20020004515A1 (en) * 1997-06-18 2002-01-10 Smith Stephen Alistair Treatment of diabetes with thiazolidinedione and metformin
AU778947B2 (en) * 1997-06-18 2004-12-23 Smithkline Beecham Plc Treatment of diabetes with thiazolidinedione and metformin
AU783539B2 (en) * 1997-06-18 2005-11-10 Smithkline Beecham Plc Treatment of diabetes with thiazolidinedione and sulphonylurea
US20010049380A1 (en) * 1997-06-18 2001-12-06 Smith Stephen Alistair Treatment of diabetes with thiazolidinedione and sulphonylurea
ATE355840T1 (de) * 1997-06-18 2007-03-15 Smithkline Beecham Plc Behandlung der diabetes mit thiazolidindione und metformin
IL133138A0 (en) * 1997-06-18 2001-03-19 Smithkline Beecham Plc Treatment of diabetes with thiazolidinedione and alpha-glucosidase inhibitor
KR20080011356A (ko) * 1997-06-18 2008-02-01 스미스클라인비이참피이엘시이 티아졸리딘디온 및 술포닐우레아를 사용한 당뇨병의 치료
US20020028768A1 (en) * 1997-06-18 2002-03-07 Smithkline Beecham P.L.C. Treatment of diabetes with rosiglitazone and insulin
GB9715298D0 (en) * 1997-07-18 1997-09-24 Smithkline Beecham Plc Novel method of treatment
AU782419B2 (en) * 1997-07-18 2005-07-28 Smithkline Beecham Plc Treatment of diabetes with thiazolidinedione, insulin secretagogue and diguanide
GB9715306D0 (en) * 1997-07-18 1997-09-24 Smithkline Beecham Plc Novel method of treatment
GB9715295D0 (en) * 1997-07-18 1997-09-24 Smithkline Beecham Plc Novel method of treatment
US20020016287A1 (en) * 1997-07-18 2002-02-07 Smithkline Beecham P.L.C. Treatment of diabetes with thiazolidinedione, insulin secretagogue and diguanide
CA2306883C (en) * 1997-10-20 2007-11-27 Dainippon Pharmaceutical Co., Ltd. Fast-dissolving pharmaceutical composition comprising as-3201
US6583157B2 (en) 1998-01-29 2003-06-24 Tularik Inc. Quinolinyl and benzothiazolyl modulators
DE69939864D1 (de) 1998-01-29 2008-12-18 Amgen Inc Ppar-gamma modulatoren
US6099859A (en) 1998-03-20 2000-08-08 Andrx Pharmaceuticals, Inc. Controlled release oral tablet having a unitary core
US7105552B2 (en) * 1998-05-08 2006-09-12 Theracos, Inc. Heterocyclic analogs of diphenylethylene compounds
US6221897B1 (en) * 1998-06-10 2001-04-24 Aventis Pharma Deutschland Gmbh Benzothiepine 1,1-dioxide derivatives, a process for their preparation, pharmaceuticals comprising these compounds, and their use
ID27415A (id) * 1998-06-30 2001-04-05 Takeda Chemical Industries Ltd Komposisi farmaseutik
JP2000080047A (ja) * 1998-06-30 2000-03-21 Takeda Chem Ind Ltd 医 薬
EP0974356B1 (en) * 1998-07-15 2003-09-24 Merck Sante Tablets comprising a combination of metformin and glibenclamide
US6376549B1 (en) * 1998-09-17 2002-04-23 Akesis Pharmaceuticals, Inc. Metforimin-containing compositions for the treatment of diabetes
KR20010089381A (ko) 1998-10-29 2001-10-06 파라비 레이 조산 또는 수유시에 자궁 수축과 같은 옥시토신 매개된작용을 차단하는 다른 물질과 병용하는티아졸리딘에디온의 임상적인 용도
NZ511614A (en) * 1998-11-12 2003-12-19 Smithkline Beecham P Modified release pharmaceutical composition containing the insulin sensitiser 5-[4-[2-(N-methyl-N-(2- pyridyl)amino)ethoxy]benzyl]thiazolidine-2,4-dione and the antidiabetic agent metaformin
AP1692A (en) * 1998-11-12 2006-12-12 Smithkline Beecham Plc Pharmaceutical composition for modified release of an insulin sensitiser and another antidiabetic agent.
DZ2937A1 (fr) * 1998-11-12 2004-03-15 Smithkline Beecham Plc Compositions nouvelles de sensibilidants à l'insuline.
US20040081697A1 (en) * 1998-11-12 2004-04-29 Smithkline Beecham P.L.C. Pharmaceutical composition for modified release of an insulin sensitiser and another antidiabetic agent
US20030153607A1 (en) * 1998-11-12 2003-08-14 Smithkline Beecham P.L.C. Novel composition and use
US20040102486A1 (en) * 1998-11-12 2004-05-27 Smithkline Beecham Corporation Novel method of treatment
US6958324B2 (en) * 1998-12-02 2005-10-25 Inotek Pharmaceuticals Corporation Inosine compounds and their use for treating or preventing an inflamation or a reperfusion disease
US20080269265A1 (en) * 1998-12-22 2008-10-30 Scott Miller Inhibition Of Raf Kinase Using Symmetrical And Unsymmetrical Substituted Diphenyl Ureas
CA2354053A1 (en) * 1998-12-24 2000-07-06 Metabasis Therapeutics, Inc. A combination of fbpase inhibitors and insulin sensitizers for the treatment of diabetes
US6756360B1 (en) 1998-12-24 2004-06-29 Metabasis Therapeutics, Inc. Combination of FBPase inhibitors and insulin sensitizers for the treatment of diabetes
AU2320600A (en) * 1999-01-29 2000-08-18 Takeda Chemical Industries Ltd. Compressing mallet with coating treatment
JP4799720B2 (ja) * 1999-01-29 2011-10-26 武田薬品工業株式会社 コーティング処理を施した打錠用杵
GB0001662D0 (en) * 1999-02-06 2000-03-15 Zeneca Ltd Pharmaceutical compositions
IL145712A0 (en) * 1999-04-01 2002-07-25 Esperion Therapeutics Inc Ether compounds, compositions, and uses thereof
US7407978B2 (en) * 1999-04-06 2008-08-05 Theracos, Inc. Heterocyclic analogs of diphenylethylene compounds
TWI249401B (en) * 1999-04-14 2006-02-21 Takeda Chemical Industries Ltd Agent for improving ketosis
JP2000355550A (ja) * 1999-04-14 2000-12-26 Takeda Chem Ind Ltd ケトーシス改善剤
ATE247653T1 (de) * 1999-04-23 2003-09-15 Smithkline Beecham Plc Thiazolidindionderivat und seine verwendung als antidiabetikum
GB9910693D0 (en) * 1999-05-07 1999-07-07 Univ Liverpool A compound for use in medicine
US6214842B1 (en) * 1999-05-12 2001-04-10 Michael S. Malamas Amino-thiazolidinediones useful in the treatment of insulin resistance and hyperglycemia
DE60032898T2 (de) * 1999-06-18 2007-10-25 Merck & Co., Inc. Arylthiazolidindion- und aryloxazolidinderivate
CA2349865C (en) 1999-06-21 2014-08-19 Eli Lilly And Company Synergistic use of thiazolidinediones with glucagon-like peptide-1 and agonists thereof to treat metabolic instability associated with non-insulin dependent diabetes
JP2003503356A (ja) * 1999-06-25 2003-01-28 メドトロニック ミニメド インコーポレイテッド 多剤糖尿病治療
DK1192137T3 (da) * 1999-06-30 2013-11-11 Amgen Inc Forbindelser til modulering af PPAR-gamma aktivitet
AU779730B2 (en) * 1999-06-30 2005-02-10 Amgen, Inc. Compounds for the modulation of PPARgamma activity
US7041691B1 (en) 1999-06-30 2006-05-09 Amgen Inc. Compounds for the modulation of PPARγ activity
AU2005200818B2 (en) * 1999-09-17 2008-07-17 Novartis Ag Method of treating metabolic disorders, especially diabetes, or a disease or condition associated with diabetes
AR028299A1 (es) * 1999-09-17 2003-05-07 Novartis Ag Una composicion farmaceutica que comprende nateglinida, un proceso para su preparacion y el uso de dicha composicion para la preparacion de un medicamento para el tratamiento de desordenes metabolicos, especialmente diabetes, o de una enfermedad o condicion asociada con diabetes.
US6878749B2 (en) * 1999-09-17 2005-04-12 Novartis Ag Method of treating metabolic disorders, especially diabetes, or a disease or condition associated with diabetes
US6559188B1 (en) 1999-09-17 2003-05-06 Novartis Ag Method of treating metabolic disorders especially diabetes, or a disease or condition associated with diabetes
US6414002B1 (en) 1999-09-22 2002-07-02 Bristol-Myers Squibb Company Substituted acid derivatives useful as antidiabetic and antiobesity agents and method
US7169407B1 (en) * 1999-10-06 2007-01-30 Toshio Miyata Carbonyl stress-decreasing agent
AU1133901A (en) * 1999-10-08 2001-04-23 Novartis Ag Method of treating metabolic disorders
US6274622B1 (en) * 1999-10-27 2001-08-14 Frederick H. Hausheer Method of treating diabetic ophthalmopathy
MXPA02004282A (es) 1999-11-03 2003-02-17 Squibb Bristol Myers Co Metodo para tratar la diabetes.
US6586438B2 (en) * 1999-11-03 2003-07-01 Bristol-Myers Squibb Co. Antidiabetic formulation and method
AR030920A1 (es) * 1999-11-16 2003-09-03 Smithkline Beecham Plc Composiciones farmaceuticas para el tratamiento de la diabetes mellitus y condiciones asociadas con la diabetes mellitus, y procedimientos para preparar dichas composiciones
US6402771B1 (en) 1999-12-23 2002-06-11 Guidant Endovascular Solutions Snare
US6660021B1 (en) 1999-12-23 2003-12-09 Advanced Cardiovascular Systems, Inc. Intravascular device and system
US6575997B1 (en) 1999-12-23 2003-06-10 Endovascular Technologies, Inc. Embolic basket
GB9930688D0 (en) * 1999-12-24 2000-02-16 Smithkline Beecham Plc Novel method of treatment
JP2003518493A (ja) * 1999-12-24 2003-06-10 スミスクライン ビーチャム パブリック リミテッド カンパニー 新規治療方法
US7918820B2 (en) 1999-12-30 2011-04-05 Advanced Cardiovascular Systems, Inc. Device for, and method of, blocking emboli in vessels such as blood arteries
US6695813B1 (en) 1999-12-30 2004-02-24 Advanced Cardiovascular Systems, Inc. Embolic protection devices
US20010036479A1 (en) 2000-01-14 2001-11-01 Gillian Cave Glyburide composition
WO2001052860A2 (en) * 2000-01-24 2001-07-26 Inotek Corporation Method and composition for modulating an immune response
US6540982B1 (en) * 2000-01-25 2003-04-01 Aeropharm Technology Incorporated Medical aerosol formulation
EP1254667A4 (en) * 2000-02-10 2003-03-12 Takeda Chemical Industries Ltd MEDICINE COMPRISING A COMBINATION
CA2401356A1 (en) * 2000-02-24 2001-08-30 Takeda Chemical Industries, Ltd. Combination drug
US6610272B1 (en) * 2000-05-01 2003-08-26 Aeropharm Technology Incorporated Medicinal aerosol formulation
US6548049B1 (en) * 2000-05-01 2003-04-15 Aeropharm Technology Incorporated Medicinal aerosol formulation
US6296874B1 (en) * 2000-05-01 2001-10-02 Aeropharm Technology Incorporated Core formulation comprising troglitazone and abiguanide
US6524621B2 (en) 2000-05-01 2003-02-25 Aeropharm Technology Inc. Core formulation
US6451342B2 (en) 2000-05-01 2002-09-17 Aeropharm Technology Incorporated Core formulation comprised of troglitazone and a biguanide
US6461639B2 (en) 2000-05-01 2002-10-08 Aeropharm Technology, Inc. Core formulation
WO2001082916A2 (en) 2000-05-03 2001-11-08 Tularik Inc. Combination therapeutic compositions and methods of use
US6270797B1 (en) * 2000-05-18 2001-08-07 Usv Limited Sustained release pharmaceutical composition containing glipizide and method for producing same
US6939362B2 (en) * 2001-11-27 2005-09-06 Advanced Cardiovascular Systems, Inc. Offset proximal cage for embolic filtering devices
US20030171399A1 (en) 2000-06-28 2003-09-11 Tularik Inc. Quinolinyl and benzothiazolyl modulators
US7563774B2 (en) 2000-06-29 2009-07-21 Metabasis Therapeutics, Inc. Combination of FBPase inhibitors and antidiabetic agents useful for the treatment of diabetes
US6964670B1 (en) 2000-07-13 2005-11-15 Advanced Cardiovascular Systems, Inc. Embolic protection guide wire
US20060089389A1 (en) * 2000-08-22 2006-04-27 Malcolm Allison Combination
AR033390A1 (es) * 2000-08-22 2003-12-17 Novartis Ag Una composicion farmaceutica que comprende un antagonista del receptor at1 y un potenciador de la secrecion de insulina, el uso de dicha composicion para la fabricacion de un medicamento y un kit de partes
US7276249B2 (en) * 2002-05-24 2007-10-02 Elan Pharma International, Ltd. Nanoparticulate fibrate formulations
US20030224058A1 (en) * 2002-05-24 2003-12-04 Elan Pharma International, Ltd. Nanoparticulate fibrate formulations
US20080241070A1 (en) * 2000-09-21 2008-10-02 Elan Pharma International Ltd. Fenofibrate dosage forms
SK4112003A3 (en) * 2000-10-12 2004-01-08 Nissan Chemical Ind Ltd Preventives and remedies for complications of diabetes
US6506203B1 (en) 2000-12-19 2003-01-14 Advanced Cardiovascular Systems, Inc. Low profile sheathless embolic protection system
PL362687A1 (en) 2001-01-12 2004-11-02 Sun Pharmaceutical Industries Limited Spaced drug delivery system
AU2002248464A1 (en) 2001-02-21 2002-09-12 Medtronic Minimed, Inc. Stabilized insulin formulations
ES2240657T3 (es) 2001-02-28 2005-10-16 Pfizer Products Inc. Compuestos de sulfonilpiridazinona utiles como inhibidores de aldosa reductasa.
DE50207110D1 (de) * 2001-03-02 2006-07-20 Lichtwer Pharma Gmbh Kombinationspräparat zur behandlung des diabetes mellitus
KR200249057Y1 (ko) * 2001-03-22 2001-10-19 김진환 뚜껑, 받침대에 합체된 하수역류. 악취방지 장치
NZ528406A (en) 2001-03-30 2004-03-26 Pfizer Prod Inc Pyridazinone aldose reductase inhibitors
KR20030087051A (ko) * 2001-04-03 2003-11-12 야마노우치세이야쿠 가부시키가이샤 아릴에텐술폰아미드 유도체의 신규한 용도
PT1377276E (pt) * 2001-04-10 2011-12-30 Sun Pharma Advanced Res Co Ltd Composição de libertação temporizada por pulso
SE0101982D0 (sv) * 2001-06-01 2001-06-01 Astrazeneca Ab Pharmaceutical combination
JP2002360666A (ja) * 2001-06-11 2002-12-17 Takeda Chem Ind Ltd コバルト合金を用いた打錠用杵臼
US6737401B2 (en) * 2001-06-28 2004-05-18 Metronic Minimed, Inc. Methods of evaluating protein formulation stability and surfactant-stabilized insulin formulations derived therefrom
US7338510B2 (en) 2001-06-29 2008-03-04 Advanced Cardiovascular Systems, Inc. Variable thickness embolic filtering devices and method of manufacturing the same
US6599307B1 (en) 2001-06-29 2003-07-29 Advanced Cardiovascular Systems, Inc. Filter device for embolic protection systems
JP2004536841A (ja) * 2001-07-10 2004-12-09 エアロファーム テクノロジー インコーポレイテッド コア製剤
JP2004536843A (ja) * 2001-07-10 2004-12-09 エアロファーム テクノロジー インコーポレイテッド ピオグリタゾンおよびビグアナイドを含むコア製剤
US6638294B1 (en) 2001-08-30 2003-10-28 Advanced Cardiovascular Systems, Inc. Self furling umbrella frame for carotid filter
US6592606B2 (en) 2001-08-31 2003-07-15 Advanced Cardiovascular Systems, Inc. Hinged short cage for an embolic protection device
US8262689B2 (en) 2001-09-28 2012-09-11 Advanced Cardiovascular Systems, Inc. Embolic filtering devices
WO2003048140A1 (fr) 2001-12-03 2003-06-12 Japan Tobacco Inc. Compose azole et utilisation medicinale de celui-ci
US7241304B2 (en) 2001-12-21 2007-07-10 Advanced Cardiovascular Systems, Inc. Flexible and conformable embolic filtering devices
DE10200138A1 (de) * 2002-01-04 2003-07-17 Karl Winkler Kombination von einem PPAR-Agonisten mit PPAR-alpha Aktivität mit einem Induktor des LDL-Rezeptors
TWI327462B (en) * 2002-01-18 2010-07-21 Sumitomo Chemical Co Condensed heterocyclic sulfonyl urea compound, a herbicide containing the same, and a method for weed control using the same
US6682759B2 (en) 2002-02-01 2004-01-27 Depomed, Inc. Manufacture of oral dosage forms delivering both immediate-release and sustained-release drugs
US20030187074A1 (en) * 2002-03-04 2003-10-02 Javed Hussain Oral compositions for treatment of diabetes
TW200810743A (en) * 2002-03-22 2008-03-01 Novartis Ag Combination of organic compounds
AU2003235120A1 (en) * 2002-04-26 2003-11-10 Takeda Chemical Industries, Ltd. Screening method
US20070264348A1 (en) * 2002-05-24 2007-11-15 Elan Pharma International, Ltd. Nanoparticulate fibrate formulations
AU2002356419A1 (en) 2002-06-17 2003-12-31 Themis Laboratories Private Limited Multilayer tablets containing thiazolidinedione and biguanides and methods for producing them
EP1549296A4 (en) 2002-08-02 2006-08-09 Penwest Pharmaceuticals Co METFORMIN FORMULATIONS WITH DELAYED RELEASE
US7232828B2 (en) * 2002-08-10 2007-06-19 Bethesda Pharmaceuticals, Inc. PPAR Ligands that do not cause fluid retention, edema or congestive heart failure
US8084058B2 (en) 2002-09-20 2011-12-27 Watson Pharmaceuticals, Inc. Pharmaceutical formulation containing a biguanide and a thiazolidinedione derivative
US9060941B2 (en) * 2002-09-20 2015-06-23 Actavis, Inc. Pharmaceutical formulation containing a biguanide and a thiazolidinedione derivative
US7959946B2 (en) 2002-09-20 2011-06-14 Watson Pharmaceuticals, Inc. Pharmaceutical formulation containing a biguanide and a thiazolidinedione derivative
US7785627B2 (en) * 2002-09-20 2010-08-31 Watson Pharmaceuticals, Inc. Pharmaceutical formulation containing a biguanide and a thiazolidinedione derivative
WO2004026241A2 (en) 2002-09-20 2004-04-01 Andrx Labs Llc Multistage formulation containing a biguanide and thiazolidindione derivatives
US7252675B2 (en) 2002-09-30 2007-08-07 Advanced Cardiovascular, Inc. Embolic filtering devices
US7331973B2 (en) 2002-09-30 2008-02-19 Avdanced Cardiovascular Systems, Inc. Guide wire with embolic filtering attachment
UA80991C2 (en) * 2002-10-07 2007-11-26 Solid preparation containing an insulin resistance improving drug and an active ingredient useful as a remedy for diabetes
US20040088000A1 (en) 2002-10-31 2004-05-06 Muller Paul F. Single-wire expandable cages for embolic filtering devices
DE10252666A1 (de) * 2002-11-11 2004-08-05 Grünenthal GmbH N-Piperidyl-cyclohexan-Derivate
IN192749B (el) * 2002-11-15 2004-05-15 Ranbaxy Lab Ltd
DE10261067A1 (de) * 2002-12-24 2004-08-05 Nutrinova Nutrition Specialties & Food Ingredients Gmbh Cholesterinsenkendes Mittel, enthaltend eine n-3-Fettsäure
CN102558155A (zh) 2003-01-14 2012-07-11 阿伦纳药品公司 作为代谢调节剂的芳基和杂芳基衍生物及其所涉及的疾病如糖尿病和高血糖症的预防和治疗
US6794401B2 (en) * 2003-01-17 2004-09-21 Bexel Pharmaceuticals, Inc. Amino acid phenoxy ethers
US7179941B2 (en) 2003-01-23 2007-02-20 Sanofi-Aventis Deutschland Gmbh Carbonylamino-substituted acyl phenyl urea derivatives, process for their preparation and their use
DE10302452B4 (de) * 2003-01-23 2005-02-24 Aventis Pharma Deutschland Gmbh Carbonylamino-substituierte Acyl-phenyl-harnstoffderivate, Verfahren zu deren Herstellung und deren Verwendung
US7976853B2 (en) * 2003-01-29 2011-07-12 Takeda Pharmaceutical Company Limited Process for producing coated preparation
US7572910B2 (en) * 2003-02-20 2009-08-11 Pfizer, Inc. Pyridazinone aldose reductase inhibitors
US8591540B2 (en) 2003-02-27 2013-11-26 Abbott Cardiovascular Systems Inc. Embolic filtering devices
US20060210633A1 (en) * 2003-04-03 2006-09-21 Sun Pharmaceutical Industries Limited Programmed drug delivery system
JP3819415B2 (ja) * 2003-04-09 2006-09-06 日本たばこ産業株式会社 複素芳香５員環化合物及びその医薬用途
US7820158B2 (en) * 2003-04-10 2010-10-26 Surmodics, Inc. Ligand-coupled initiator polymers and methods of use
CA2524175C (en) * 2003-04-28 2016-06-14 Sankyo Company Limited Sugar intake-ability enhancer
ES2421520T3 (es) * 2003-04-28 2013-09-03 Daiichi Sankyo Co Ltd Potenciador de la producción de adiponectina
US20050059708A1 (en) * 2003-05-13 2005-03-17 Karel Pospisilik Processes for making thiazolidinedione derivatives and compounds thereof
US7230016B2 (en) * 2003-05-13 2007-06-12 Synthon Ip Inc. Pioglitazone salts, such as pioglitazone sulfate, and pharmaceutical compositions and processes using the same
US20050004179A1 (en) * 2003-05-22 2005-01-06 Pedersen Ward A. Methods and materials for treating, detecting, and reducing the risk of developing Alzheimer's Disease
WO2005000299A1 (en) * 2003-06-27 2005-01-06 Dr. Reddy's Research Foundation Compositions comprising balaglitazone and further antidiabetic compounds
US20050013863A1 (en) 2003-07-18 2005-01-20 Depomed, Inc., A Corporation Of The State Of California Dual drug dosage forms with improved separation of drugs
EP1651251A4 (en) * 2003-07-31 2008-06-18 Bayer Pharmaceuticals Corp METHOD FOR THE TREATMENT OF DIABETES AND RELATED DISEASES USING PDE 10A INHIBITORS
EP1510208A1 (en) * 2003-08-22 2005-03-02 Fournier Laboratories Ireland Limited Pharmaceutical composition comprising a combination of metformin and statin
US20050054731A1 (en) * 2003-09-08 2005-03-10 Franco Folli Multi-system therapy for diabetes, the metabolic syndrome and obesity
US7223761B2 (en) 2003-10-03 2007-05-29 Amgen Inc. Salts and polymorphs of a potent antidiabetic compound
EP1701735A4 (en) * 2003-10-27 2009-12-09 Innodia Inc METHODS AND COMPOSITIONS FOR USE IN THE TREATMENT OF DIABETES
TWI339586B (en) * 2003-10-31 2011-04-01 Takeda Chemical Industries Ltd Solid preparation comprising pioglitazone or salt thereof,glimpiride and polyoxyethylene sorbitan fatty acid ester
US7892251B1 (en) 2003-11-12 2011-02-22 Advanced Cardiovascular Systems, Inc. Component for delivering and locking a medical device to a guide wire
US20050163842A1 (en) * 2003-12-31 2005-07-28 Garth Boehm Rosiglitazone and metformin formulations
WO2005065654A2 (en) * 2003-12-31 2005-07-21 Alpharma, Inc. Rosiglitazone formulations
US7360069B2 (en) * 2004-01-13 2008-04-15 Hewlett-Packard Development Company, L.P. Systems and methods for executing across at least one memory barrier employing speculative fills
TWI297606B (en) * 2004-01-16 2008-06-11 Nat Health Research Institutes Cancer therapy
CA2555316A1 (en) * 2004-02-09 2005-08-18 Aska Pharmaceutical Co., Ltd. Combined pharmaceutical composition
WO2005080387A2 (en) * 2004-02-20 2005-09-01 Synthon B.V. Processes for making pioglitazone and compounds of the processes
JP2007526309A (ja) * 2004-03-02 2007-09-13 アベール ファーマシューティカルズ インコーポレイテッド 生物活性剤の混合製剤またはキット
US7678129B1 (en) 2004-03-19 2010-03-16 Advanced Cardiovascular Systems, Inc. Locking component for an embolic filter assembly
US7161756B2 (en) * 2004-05-10 2007-01-09 Tandberg Data Storage Asa Method and system for communication between a tape drive and an external device
CN1327840C (zh) * 2004-06-08 2007-07-25 天津药物研究院 一种药物组合物及其在制备用于治疗糖尿病中的应用
EP1773376A4 (en) * 2004-08-03 2009-07-01 Emisphere Tech Inc ANTIDIBLE ORAL INSULIN BIGUANIDE COMBINATION
US20060193845A1 (en) * 2004-09-14 2006-08-31 Elixir Pharmaceuticals, Inc. Combination therapy for controlled carbohydrate digestion
MXPA04009236A (es) * 2004-09-23 2006-03-27 Jorge Luis Rosado Loria Composicion sinergistica para el tratamiento de diabetes y sus comorbilidades.
JP2008019169A (ja) * 2004-10-25 2008-01-31 Osaka Univ 新規ｐｐａｒ調節剤およびそのスクリーニング方法
US20060089387A1 (en) * 2004-10-26 2006-04-27 Le Huang Stabilized pharmaceutical composition comprising antidiabetic agent
US7833513B2 (en) 2004-12-03 2010-11-16 Rhode Island Hospital Treatment of Alzheimer's Disease
US9259305B2 (en) 2005-03-31 2016-02-16 Abbott Cardiovascular Systems Inc. Guide wire locking mechanism for rapid exchange and other catheter systems
US20100028439A1 (en) * 2005-05-23 2010-02-04 Elan Pharma International Limited Nanoparticulate stabilized anti-hypertensive compositions
GT200600218A (es) * 2005-06-10 2007-03-28 Formulación y proceso de compresión directa
KR100964330B1 (ko) * 2005-07-07 2010-06-17 학교법인 포항공과대학교 당흡수 조절제 및 당뇨병 또는 당뇨병 합병증의 치료방법
WO2007011524A1 (en) * 2005-07-14 2007-01-25 Franco Folli Daily dosage regimen for treating diabetes, obsity, metabolic syndrome and polycystic ovary syndrome
MX2008001063A (es) * 2005-07-22 2008-03-19 Procter & Gamble Composiciones para reducir la incidencia de arritmia inducida por farmacos.
MXPA05013220A (es) * 2005-12-06 2007-06-05 Leopoldo De Jesus Espinosa Abdala Composiciones farmaceuticas que comprenden sustancias antidiabeticas combinadas para su uso en diabetes mellitus tipo 2.
AU2006328328B2 (en) 2005-12-22 2012-08-30 Takeda Pharmaceutical Company Limited Solid preparation containing an insulin sensitizer
FR2896157B1 (fr) 2006-01-13 2008-09-12 Merck Sante Soc Par Actions Si Combinaison de derives de triazine et d'agents de stimulation de secretion d'insuline.
WO2007105730A1 (ja) * 2006-03-13 2007-09-20 Kyowa Hakko Kogyo Co., Ltd. インスリン抵抗性改善剤
NZ571871A (en) 2006-03-16 2011-07-29 Metabolic Solutions Dev Co Thiazolidinedione analogues for the treatment of metabolic inflammation mediated disease
KR20080106455A (ko) * 2006-03-31 2008-12-05 웰스태트 테러퓨틱스 코포레이션 대사장애의 조합치료
US7727404B2 (en) * 2006-04-11 2010-06-01 Sorbwater Technology As Method for removal of materials from a liquid stream
US7435741B2 (en) 2006-05-09 2008-10-14 Teva Pharmaceutical Industries, Ltd. 2-N{5-[[4-[2-(methyl-2-pyridinylamino) ethoxy] phenyl]methyl]-2,4-thiazolidinedione} butanedioic acid, methods of preparation and compositions with rosiglitazone maleate
CA2787343C (en) 2006-06-26 2016-08-02 Amgen Inc. Compositions comprising modified lcat and uses thereof
US7752724B2 (en) * 2006-06-27 2010-07-13 Lumino, Inc. Method of cutting blinds
WO2008026668A1 (fr) * 2006-08-31 2008-03-06 Daiichi Sankyo Company, Limited Composition médicale contenant un agent d'amélioration de la résistance à l'insuline
US20080182880A1 (en) * 2006-09-28 2008-07-31 Mailatur Sivaraman Mohan Pioglitazone composition
US8217025B2 (en) * 2006-11-17 2012-07-10 Harbor Therapeutics, Inc. Drug screening and treatment methods
EP2016076A2 (en) * 2007-01-22 2009-01-21 Teva Pharmaceutical Industries Ltd. Polymorphic forms of rosiglitazone hydrobromide and processes for preparation thereof
AU2008209320B2 (en) 2007-01-25 2013-05-30 NAIA Metabolic, Inc. Insulin sensitisers and methods of treatment
TWI453041B (zh) * 2007-02-01 2014-09-21 Takeda Pharmaceutical 固體型製劑
US20080249156A1 (en) * 2007-04-09 2008-10-09 Palepu Nageswara R Combinations of statins and anti-obesity agent and glitazones
WO2008128126A1 (en) 2007-04-11 2008-10-23 Omeros Corporation Compositions and methods for prophylaxis and treatment of addictions
US20160331729A9 (en) 2007-04-11 2016-11-17 Omeros Corporation Compositions and methods for prophylaxis and treatment of addictions
US11241420B2 (en) 2007-04-11 2022-02-08 Omeros Corporation Compositions and methods for prophylaxis and treatment of addictions
US8216209B2 (en) 2007-05-31 2012-07-10 Abbott Cardiovascular Systems Inc. Method and apparatus for delivering an agent to a kidney
US8969514B2 (en) 2007-06-04 2015-03-03 Synergy Pharmaceuticals, Inc. Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases
WO2008151257A2 (en) 2007-06-04 2008-12-11 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders
US7867273B2 (en) 2007-06-27 2011-01-11 Abbott Laboratories Endoprostheses for peripheral arteries and other body vessels
US8168416B2 (en) 2007-07-26 2012-05-01 Amgen Inc. Modified lecithin-cholesterol acyltransferase enzymes
EP2203433B1 (en) * 2007-09-14 2012-10-31 Metabolic Solutions Development Company LLC 5-(4-(2-(3-methoxyphenyl)-2-oxoethoxy)benzyl)thiazolidine-2,4-dione for use in treating diabetes
WO2009038107A1 (ja) * 2007-09-21 2009-03-26 Kissei Pharmaceutical Co., Ltd. ２型糖尿病治療用の組合せ医薬
US20100311092A1 (en) * 2007-11-30 2010-12-09 Kurland Irwin J Metabolic fuel switching biomarker
US8551524B2 (en) 2008-03-14 2013-10-08 Iycus, Llc Anti-diabetic combinations
EP2190417A2 (en) * 2008-03-26 2010-06-02 Teva Pharmaceutical Industries Ltd. Pharmaceutical compositions comprising insulin sensitizer and insulin secretagogue
AU2009256157B2 (en) 2008-06-04 2014-12-18 Bausch Health Ireland Limited Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders
EP2321341B1 (en) 2008-07-16 2017-02-22 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase useful for the treatment of gastrointestinal, inflammation, cancer and other disorders
CN102177436B (zh) 2008-08-12 2015-05-13 金帆德尔制药股份有限公司 鉴定疾病风险因子的方法
US8846315B2 (en) 2008-08-12 2014-09-30 Zinfandel Pharmaceuticals, Inc. Disease risk factors and methods of use
TW201031664A (en) 2009-01-26 2010-09-01 Targacept Inc Preparation and therapeutic applications of (2S,3R)-N-2-((3-pyridinyl)methyl)-1-azabicyclo[2.2.2]oct-3-yl)-3,5-difluorobenzamide
CN102348457A (zh) 2009-03-11 2012-02-08 奥默罗斯公司 预防和治疗成瘾的组合物和方法
US20110038848A1 (en) * 2009-08-12 2011-02-17 Melaleuca, Inc. Dietary supplement compositions for cardiovascular health
CN102655866B (zh) 2009-11-13 2013-11-13 东丽株式会社 糖尿病的治疗或预防药
KR101851130B1 (ko) * 2009-12-04 2018-04-23 센화 바이오사이언시즈 인코포레이티드 Ｃｋ2 억제제로서 피라졸로피리미딘 및 관련된 헤테로사이클
JP2013514368A (ja) * 2009-12-15 2013-04-25 メタボリック ソリューションズ ディベロップメント カンパニー， エルエルシー 神経変性疾患を処置するための、ｐｐａｒ温存チアゾリジンジオンおよび組み合わせ物
US8912335B2 (en) * 2009-12-15 2014-12-16 Metabolic Solutions Development Company, Llc PPAR-sparing thiazolidinedione salts for the treatment of metabolic diseases
EP2552442A1 (en) 2010-03-30 2013-02-06 Boehringer Ingelheim International GmbH Pharmaceutical composition comprising an sglt2 inhibitor and a ppar- gamma agonist and uses thereof
WO2011127051A1 (en) * 2010-04-06 2011-10-13 Arena Pharmaceuticals, Inc. Modulators of the gpr119 receptor and the treatment of disorders related thereto
RU2526153C2 (ru) * 2010-07-15 2014-08-20 Олег Ильич Эпштейн Способ повышения фармакологической активности действующего вещества лекарственного средства и фармацевтическая композиция
JP2013538807A (ja) 2010-09-01 2013-10-17 ルピン・リミテッド メトホルミンおよびピオグリタゾンを含む医薬組成物
US9616097B2 (en) 2010-09-15 2017-04-11 Synergy Pharmaceuticals, Inc. Formulations of guanylate cyclase C agonists and methods of use
US10894787B2 (en) 2010-09-22 2021-01-19 Arena Pharmaceuticals, Inc. Modulators of the GPR119 receptor and the treatment of disorders related thereto
MX355479B (es) 2011-01-10 2018-04-19 Zinfandel Pharmaceuticals Inc Metodos y productos de farmaco para tratar enfermedad de alzheimer.
RU2013135224A (ru) * 2011-01-20 2015-03-10 Бионевиа Фармасьютикалс Инк. Композиции с модифицированным высвобождением эпалрестата или его производных и способы их использования
WO2013034174A1 (en) 2011-09-06 2013-03-14 ZENTIVA Saglik Ürünleri Sanayi ve Ticaret A.S. Solid preparations of pioglitazone and glimepiride
CA2853285C (en) 2011-10-28 2020-05-05 Lumena Pharmaceuticals, Inc. Bile acid recycling inhibitors for treatment of pediatric cholestatic liver diseases
EP2788384B1 (en) 2011-12-08 2017-08-09 Amgen Inc. Agonistic human lcat antigen binding proteins and their use in therapy
US9504679B2 (en) 2011-12-19 2016-11-29 Bjoern Colin Kahrs Pharmaceutical compositions comprising glitazones and Nrf2 activators
US20130158077A1 (en) 2011-12-19 2013-06-20 Ares Trading S.A. Pharmaceutical compositions
AU2014235209B2 (en) 2013-03-15 2018-06-14 Bausch Health Ireland Limited Guanylate cyclase receptor agonists combined with other drugs
WO2014151206A1 (en) 2013-03-15 2014-09-25 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase and their uses
WO2014197720A2 (en) 2013-06-05 2014-12-11 Synergy Pharmaceuticals, Inc. Ultra-pure agonists of guanylate cyclase c, method of making and using same
JP2016534043A (ja) 2013-10-09 2016-11-04 シナジー ファーマシューティカルズ インコーポレイテッド 炎症促進性サイトカインのダウンレギュレーションに有用なグアニル酸シクラーゼのアゴニスト
RU2572706C1 (ru) * 2014-06-30 2016-01-20 Олег Ильич Эпштейн Способ повышения фармакологической активности действующего вещества лекарственного средства и фармацевтическая композиция
AR103624A1 (es) 2015-02-06 2017-05-24 Intercept Pharmaceuticals Inc Composiciones farmacéuticas para terapia de combinación
HUE060476T2 (hu) 2015-06-22 2023-03-28 Arena Pharm Inc (R)-2-(7-(4-ciklopentil-3-(trifluormetil)benziloxi)-1,2,3,4- tetrahidrociklopenta[B]indol-3-il)ecetsav kristályos L-arginin-sója S1P1 receptorral kapcsolatos rendellenességek esetén való alkalmazásra
WO2018130679A1 (en) 2017-01-16 2018-07-19 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and pharmaceutical compositions for reducing cd95- mediated cell motility
CA3103617A1 (en) 2018-06-14 2019-12-19 Astrazeneca Uk Limited Methods for lowering blood sugar with a metformin pharmaceutical composition
KR20220016146A (ko) 2019-05-30 2022-02-08 인터셉트 파마슈티컬즈, 인크. 담즙정체성 간 질환의 치료에서 사용하기 위한 fxr 효능제 및 피브레이트를 포함하는 제약 조성물
CN112869173A (zh) * 2021-01-18 2021-06-01 广州富诺营养科技有限公司 一种复合维生素矿物质制剂及其制备方法

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3454635A (en) * 1965-07-27 1969-07-08 Hoechst Ag Benzenesulfonyl-ureas and process for their manufacture
JPS5522636A (en) * 1978-08-04 1980-02-18 Takeda Chem Ind Ltd Thiazoliding derivative
JPS5728073A (en) * 1980-07-29 1982-02-15 Takeda Chem Ind Ltd Inhibitor for aldose reducing enzyme
US4863922A (en) * 1984-12-12 1989-09-05 Merck & Co., Inc. Substituted aromatic sulfonamides as antiglaucoma agents, compositions and use
AR240698A1 (es) * 1985-01-19 1990-09-28 Takeda Chemical Industries Ltd Procedimiento para preparar compuestos de 5-(4-(2-(5-etil-2-piridil)-etoxi)benzil)-2,4-tiazolidindiona y sus sales
AU598366B2 (en) 1987-03-20 1990-06-21 Alcon Laboratories, Inc. Use of aldose reductase inhibitors to enhance insulin sensitivity in diabetes
DE3729209A1 (de) * 1987-09-01 1989-03-09 Boehringer Mannheim Gmbh Verwendung von bezafibrat zur behandlung von diabetes
DE10199003I1 (de) 1987-09-04 2003-06-12 Beecham Group Plc Substituierte Thiazolidinionderivate
US4895862A (en) * 1989-04-21 1990-01-23 American Home Products Corp. Novel benzyl-3H-1,2,3,5-oxathiadiazole 2-oxides useful as antihyperglycemic agents
US5068342A (en) * 1989-10-27 1991-11-26 American Home Products Corporation 5-[(1- and 2-naphthalenyl)thio and sulfonyl]-2,4-thiazolidinediones and derivatives thereof
US5356913A (en) * 1990-02-09 1994-10-18 The Upjohn Company Use of insulin sensitizing agents to treat hypertension
JPH0466579A (ja) * 1990-07-04 1992-03-02 Yamanouchi Pharmaceut Co Ltd チアゾリジン誘導体
JPH0469383A (ja) * 1990-07-06 1992-03-04 Yamanouchi Pharmaceut Co Ltd 置換チアゾリジン誘導体
US5260275A (en) * 1990-08-14 1993-11-09 Amylin Pharmaceuticals, Inc. Hypoglycemics
CA2052014A1 (en) * 1990-10-19 1992-04-20 Henry Y. Pan Method for preventing diabetic complications employing a cholesterol lowering drug alone or in combination with an ace inhibitor
JP2686861B2 (ja) * 1991-03-30 1997-12-08 キッセイ薬品工業株式会社 新規なベンジリデンコハク酸誘導体
WO1993003724A1 (en) * 1991-08-26 1993-03-04 The Upjohn Company Pharmaceutical composition containing 3-guanidinopropionic acid and pioglitazone glibenclamide or glimepiride
JPH05202042A (ja) * 1992-01-24 1993-08-10 Sankyo Co Ltd 糖尿病性合併症治療剤
JPH07316144A (ja) * 1994-03-29 1995-12-05 Sankyo Co Ltd ジフェニルメチルピペラジン誘導体
TW403748B (en) * 1994-11-02 2000-09-01 Takeda Chemical Industries Ltd An oxazolidinedione derivative, its production and a pharmaceutical composition for lowering blood sugar and lipid in blood comprising the same
US5674900A (en) * 1995-06-06 1997-10-07 Shaman Pharmaceuticals, Inc. Terpenoid-type quinones for treatment of diabetes
TW438587B (en) * 1995-06-20 2001-06-07 Takeda Chemical Industries Ltd A pharmaceutical composition for prophylaxis and treatment of diabetes
NO318765B1 (no) * 1995-07-03 2005-05-02 Sankyo Co Anvendelse av en HMG-CoA reduktaseinhibitor og en insulinsensibilisator til fremstilling av et medikament for forebyggelse eller behandling av arteriosklerose eller xantom, samt pakket farmasoytisk preparat som omfatter de to midlene i separate porsjoner.
US6011049A (en) 1997-02-19 2000-01-04 Warner-Lambert Company Combinations for diabetes
US5859037A (en) * 1997-02-19 1999-01-12 Warner-Lambert Company Sulfonylurea-glitazone combinations for diabetes
GB9715298D0 (en) * 1997-07-18 1997-09-24 Smithkline Beecham Plc Novel method of treatment
US6001049A (en) * 1998-02-12 1999-12-14 Frey; Mark P. Light weight exercise apparatus

Also Published As

Publication number Publication date
US20110034518A1 (en) 2011-02-10
US20070203198A1 (en) 2007-08-30
CN1212117C (zh) 2005-07-27
NO20021172L (no) 1996-12-23
US6329404B1 (en) 2001-12-11
MY127530A (en) 2006-12-29
US6599923B2 (en) 2003-07-29
US6225326B1 (en) 2001-05-01
RU2223760C2 (ru) 2004-02-20
US6911459B2 (en) 2005-06-28
EP0861666A2 (en) 1998-09-02
US6232330B1 (en) 2001-05-15
NO20004345L (no) 1996-12-23
US6211206B1 (en) 2001-04-03
EP0861666A3 (en) 1999-02-10
HK1041203A1 (en) 2002-07-05
DE122009000064I1 (de) 2011-12-01
US6133293A (en) 2000-10-17
CY2424B1 (en) 2004-11-12
US6303640B1 (en) 2001-10-16
DE122007000002I1 (de) 2012-03-08
SK287287B6 (sk) 2010-05-07
KR970000233A (ko) 1997-01-21
JP3148973B2 (ja) 2001-03-26
NL300258I1 (nl) 2007-04-02
CY2007001I2 (el) 2009-11-04
NL300432I2 (en) 2010-04-01
AR065389A2 (es) 2009-06-03
NO317341B1 (no) 2004-10-11
JP3973280B2 (ja) 2007-09-12
US6150384A (en) 2000-11-21
HK1041203B (zh) 2009-09-25
JP2007191494A (ja) 2007-08-02
EP2289556A3 (en) 2011-03-09
EP0749751A3 (en) 1997-04-16
US6172090B1 (en) 2001-01-09
RU2323004C2 (ru) 2008-04-27
CN1530105A (zh) 2004-09-22
KR20070081135A (ko) 2007-08-16
NO2007001I2 (no) 2011-03-14
CA2531834C (en) 2006-12-05
US20020123512A1 (en) 2002-09-05
ATE438397T1 (de) 2009-08-15
EP0749751A2 (en) 1996-12-27
US6174904B1 (en) 2001-01-16
DK1174135T3 (da) 2009-12-07
FR09C0055I1 (el) 2009-04-12
US6214848B1 (en) 2001-04-10
US6211207B1 (en) 2001-04-03
US6080765A (en) 2000-06-27
HU9601698D0 (en) 1996-08-28
KR20080005162A (ko) 2008-01-10
RU2286148C2 (ru) 2006-10-27
CN1530106A (zh) 2004-09-22
EP1174135B9 (en) 2009-12-16
ES2212208T3 (es) 2004-07-16
HK1010484A1 (en) 1999-06-25
ATE256463T1 (de) 2004-01-15
NO20004345D0 (no) 2000-09-01
US6218409B1 (en) 2001-04-17
RU2003130978A (ru) 2005-04-20
CY2009018I1 (el) 2010-07-28
CA2179584C (en) 2007-04-24
US20040266830A1 (en) 2004-12-30
CN1145783A (zh) 1997-03-26
EP2289556A2 (en) 2011-03-02
DE122007000002I2 (de) 2012-03-08
US20030216443A1 (en) 2003-11-20
AR061195A2 (es) 2008-08-13
US6323225B1 (en) 2001-11-27
NO2007007I2 (no) 2009-10-05
CZ292093B6 (cs) 2003-07-16
US6274605B1 (en) 2001-08-14
US6121295A (en) 2000-09-19
US6156773A (en) 2000-12-05
NO962606L (no) 1996-12-23
NO314065B1 (no) 2003-01-27
US6271243B1 (en) 2001-08-07
US5952356A (en) 1999-09-14
EP0861666B1 (en) 2003-12-17
EP1174135B1 (en) 2009-08-05
CA2533845C (en) 2012-10-09
HUP9601698A3 (en) 2000-09-28
EP1764110A1 (en) 2007-03-21
US20020042434A1 (en) 2002-04-11
CZ291624B6 (cs) 2003-04-16
US6133295A (en) 2000-10-17
US6166042A (en) 2000-12-26
DE69637988D1 (de) 2009-09-17
DE69631157D1 (de) 2004-01-29
US6103742A (en) 2000-08-15
NO20021172D0 (no) 2002-03-08
ZA965190B (en) 1997-12-19
CY2009018I2 (el) 2010-07-28
US6150383A (en) 2000-11-21
SK79496A3 (en) 1997-01-08
US7144900B2 (en) 2006-12-05
DE69631157T2 (de) 2004-09-09
US6166043A (en) 2000-12-26
US20020128289A1 (en) 2002-09-12
HUP9601698A2 (hu) 1997-05-28
LU91606I2 (fr) 2009-11-09
JP4809806B2 (ja) 2011-11-09
ES2327383T5 (es) 2017-03-13
US6121294A (en) 2000-09-19
US20050054685A1 (en) 2005-03-10
PT1174135E (pt) 2009-08-31
AR091289A2 (es) 2015-01-28
US6239153B1 (en) 2001-05-29
AU5603496A (en) 1997-01-09
CA2179584A1 (en) 1996-12-21
US5965584A (en) 1999-10-12
CZ181196A3 (en) 1997-01-15
NO2007007I1 (no) 2007-06-18
NO313226B1 (no) 2002-09-02
AU723097B2 (en) 2000-08-17
CN1289082C (zh) 2006-12-13
US6211205B1 (en) 2001-04-03
DK0861666T3 (da) 2004-03-08
NL300258I2 (nl) 2007-05-01
CA2533845A1 (en) 1996-12-21
NO962606D0 (no) 1996-06-19
ES2327383T3 (es) 2009-10-29
US6169099B1 (en) 2001-01-02
EP1174135B2 (en) 2016-09-14
EP1174135A2 (en) 2002-01-23
US20020002186A1 (en) 2002-01-03
JPH10167986A (ja) 1998-06-23
NO2007001I1 (no) 2007-01-29
EP2292268A1 (en) 2011-03-09
SK287351B6 (sk) 2010-08-09
EP1174135A3 (en) 2002-06-19
US7538125B2 (en) 2009-05-26
US6384062B1 (en) 2002-05-07
CY2007001I1 (el) 2009-11-04
CA2531834A1 (en) 1996-12-21
US6172089B1 (en) 2001-01-09
US6251924B1 (en) 2001-06-26
US6277869B1 (en) 2001-08-21
FR09C0055I2 (fr) 2010-06-11
MX9602399A (es) 1997-02-28
AR005641A1 (es) 1999-07-14
US6288090B1 (en) 2001-09-11
US6169100B1 (en) 2001-01-02
NL300432I1 (en) 2010-03-01
US20090246232A1 (en) 2009-10-01
JPH0967271A (ja) 1997-03-11
RU2198682C2 (ru) 2003-02-20
US7842706B2 (en) 2010-11-30
PT861666E (pt) 2004-05-31
LU91298I2 (fr) 2007-02-20
TWI238064B (en) 2005-08-21
TW438587B (en) 2001-06-07
RU2327455C2 (ru) 2008-06-27

Similar Documents

Publication Publication Date Title
CY2608B2 (el) Φαρμακευτικη συνθεση περιλαμβανουσα πιογλιταζονη και γλιμεπιριδη για χρηση στην θεραπεια του διαβητη
CY1108587T1 (el) Φαρμακευτικη συνθεση για τροποποιημενη απελευθερωση ενος ευαισθητοποιητη ινσουλινης και μετφορμινης
CY1105254T1 (el) Θepαπεια του διαβητη με θειαζολιδινδιονη, εκκριταγωγο ινσουλινης και διγουανιδιο
CY2007018I1 (el) Αντιμετωπιση του διαβητη με θειαζολιδινοδιονη και μετφορμινη
CY1105920T1 (el) Συσκευη για τη χορηγηση φαρμακευτικης ουσιας
KR890013737A (ko) 감방사선성 수지 조성물
DK0895481T3 (da) Injektionsnål
CA2329004A1 (en) Combination of insulin sensitizer with anorectic for treating or preventing diabetes
ES2171538T3 (es) Dispositivo de inyeccion a chorro sin aguja.
CY1106195T1 (el) Θepαπεια συνδυασμου η οποια πepιλαμβανει αντιδιαβητικους και αντισπασμωδικους παραγοντες
BR9506470B1 (pt) composiÇço adesiva sensÍvel À pressço e sistema de distribuiÇço transdÉrmica de droga.
ITBO910163A1 (it) Uso dei glicosaminoglicani nel trattamento della nefropatia diabetica e della neuropatia diabetica.
CY1107745T1 (el) Αγωγη του διαβητη με θειαζολιδινοδιονη και σουλφονυλουρια
ES2183952T3 (es) Tratamiento de diabetes tipo ii con dosis elevadas de tripicolinato cromico.
KR970704440A (ko) 당뇨병 타입 ⅱ의 치료용 약물에의 케토코나졸 및 관련 물질의 용도(use of ketoconazole and related substances in medicaments for treatment of type ⅱ diabetes)
AR011106A1 (es) COMPOSICIoN FARMACÉUTICA PARA EL TRAMIENTO O PREVENCI.ON DE LA DIABETES MELLITUS TIPO 2,
KR910019620A (ko) 15-케토-프로스타글란딘 화합물을 사용한 췌장 질병의 치료
PE104499A1 (es) Composicion farmaceutica de tiazolidindiona e insulina para el tratamiento de la diabetes
DE60030085D1 (de) Geflocktes auftragungsgerät für kosmetische erzeugnisse
KR890012618A (ko) X선 화상 처리장치
CY1105463T1 (el) Ελεγχομενη χορηγηση αντικαταθλιπτικων
TR200000133T2 (tr) Tiazolidinedion, ensülin salgılattırıcısı ve alfa glükosidaz inhibitörü ile diabetin (şeker hastasının) tedavisi.
PT869785E (pt) 4-hidroxicumarina-3-carboxamidas para o tratamento de diabetes mellitus nao insulinodependente
ES2166406T3 (es) Uso de derivados de 1,5-benzodiazepina para el control del vaciado gastrico en pacientes con diabetes mellitus no dependiente de insulina.
KR900012622A (ko) 피부질환치료 조성물